跳至主要内容
临床试验/NCT03640871
NCT03640871Unknown不适用

Assessment of Efficacy, Tolerance and Acceptability for the Wound Dressing URGO AWC_019 in the Local Treatment of Acute Wounds, Chronic Wounds and Epidermolysis Bullosa Skin Lesions

Laboratoires URGO0 个研究点目标入组 80 人开始时间: 2018年10月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
80
主要终点
Relative evolution of the wound surface (in %) at week 4

研究概览

简要总结

Assessment of efficacy, tolerance and acceptability for the wound dressing URGO AWC_019 in the treatment of acute wounds, chronic wounds and epidermolysis bullosa skin lesions

详细描述

Non-comparative clinical study, conducted in France, to evaluate efficacy, tolerance and acceptability for the wound dressing URGO AWC_019 in the treatment of acute wounds, chronic wounds and epidermolysis bullosa skin lesions

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •A. Related to every wounds types:
  • •Patient over 18 years old who has provided his/her written informed consent
  • •Patient affiliated to the French Social insurance
  • •Patient who can be monitored by the same investigation team throughout the whole duration of the study,
  • •Acute wound (postoperative non-cavitary and non-sutured wound, superficial, middle or deep second degree burn, dermabrasion) or chronic wound (venous or mixed leg ulcer, pressure ulcer) or epidermolysis bullosa skin lesion
  • •Use of a contact layer as a primary dressing justified by the wound
  • •B. Related to leg ulcer:
  • •Venous leg ulcer or mixed leg ulcer, i.e. with an Ankle Brachial Pressure Index (ABPI) not less than 0.7 and not more than 1.3, (0.7≤ABPI≤ 1.3)
  • •Patient who agrees to wear an effective venous compression system every day, associated with the trial dressing
  • •C. Related to pressure ulcer:
  • •Stage 2, 3 according to the EPUAP (European Pressure Ulcer Advisory Panel) classification system
  • •Wound on the pelvis (trochanter, ischio or sacrum) or on the heel

排除标准

  • •Patient under authorship or guardianship
  • •Woman of child-bearing potential who has no effective contraception method
  • •Pregnant or breastfeeding woman
  • •Patient taking part in another clinical trial
  • •Patient with a known allergy to carboxymethylcellulose (hydrocolloid),
  • •Patient with a severe illness that might lead to the premature discontinuation of the trial before the 4 weeks of treatment
  • •Wound requiring surgical treatment or for which surgery is scheduled during the 4 weeks after inclusion
  • •Patient with an evolving neoplasia condition, treated by radiotherapy, chemotherapy or hormone therapy
  • •Malignant wound
  • •Patient with a systemic infection not controlled by suitable antibiotic treatment,
  • •Wound which is clinically infected

研究组 & 干预措施

URGO AWC_019 dressing (AWC=Advanced Wound Care)

Experimental

URGO AWC_019 dressing (AWC=Advanced Wound Care)

干预措施: URGO AWC_019 dressing (AWC=Advanced Wound Care) (Device)

结局指标

主要结局

Relative evolution of the wound surface (in %) at week 4

时间窗: 4 weeks

Relative evolution of the wound surface (in %) at week 4

次要结局

  • - Pain on wound URGO AWC_019 dressing removal (measured thanks to Analogical Visual Scale: no pain = 0 mm and unbearable pain = 100 mm)(4 weeks)
  • - Wound dressing safety (occurrence of adverse events)(4 weeks)
  • - Percentage of healed wounds (healing rate) after 4 weeks of treatment(4 weeks)
  • - Wound healing time (in days)(4 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

相似试验